^
    Back
    Association details:
    Biomarker:AR positive
    Cancer:Breast Cancer
    Drug:pruxelutamide (GT0918) (Androgen receptor antagonist, TMPRSS2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer

    Excerpt:
    ...Dose-limiting Toxicity(DLT)`100 mg, 200 mg, 300 mg, 400 mg or 500 mg of GT0918`maximum tolerated dose (MTD)`Preliminary evaluation of the DCR of GT0918 tablets in AR positive metastatic breast cancer patients, and determination of the recommended dose of proclamine in clinical trials.`...
    Trial ID:
    NCT04103853
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis

    Published date:
    09/28/2022
    Excerpt:
    Proxalutamide showed promising anti-tumour activity with good tolerability in patients with heavily pretreated AR+ mBC, supporting further investigation.
    DOI:
    10.1016/j.ejca.2022.08.025
    Trial ID:
    NCT04103853
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer Res Treat
    Title:

    Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer

    Published date:
    08/14/2021
    Excerpt:
    GT0918 was demonstrated to effectively suppress the expression of AR protein and the growth of AR-positive breast cancer tumors in mouse xenograft tumor models....GT0918 can effectively inhibit AR-positive breast cancer tumor growth.
    DOI:
    10.1007/s10549-021-06345-x